Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:GILD NASDAQ:MRNA NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$337.42+1.8%$346.62$267.83▼$391.29$182.10B0.442.75 million shs2.00 million shsGILDGilead Sciences$130.50-0.1%$136.86$104.46▼$157.29$162.02B0.316.71 million shs4.92 million shsMRNAModerna$47.26-1.8%$51.16$22.28▼$59.55$18.75B1.059.63 million shs4.78 million shsREGNRegeneron Pharmaceuticals$642.59-1.1%$736.76$476.49▼$821.11$67.93B0.3792,039 shs1.18 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.25%-1.45%-5.31%-11.70%+20.57%GILDGilead Sciences+0.15%-1.77%-3.81%-13.52%+19.78%MRNAModerna+5.25%-4.56%-11.85%-3.18%+71.92%REGNRegeneron Pharmaceuticals+3.09%-9.74%-13.33%-16.95%+5.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$337.42+1.8%$346.62$267.83▼$391.29$182.10B0.442.75 million shs2.00 million shsGILDGilead Sciences$130.50-0.1%$136.86$104.46▼$157.29$162.02B0.316.71 million shs4.92 million shsMRNAModerna$47.26-1.8%$51.16$22.28▼$59.55$18.75B1.059.63 million shs4.78 million shsREGNRegeneron Pharmaceuticals$642.59-1.1%$736.76$476.49▼$821.11$67.93B0.3792,039 shs1.18 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.25%-1.45%-5.31%-11.70%+20.57%GILDGilead Sciences+0.15%-1.77%-3.81%-13.52%+19.78%MRNAModerna+5.25%-4.56%-11.85%-3.18%+71.92%REGNRegeneron Pharmaceuticals+3.09%-9.74%-13.33%-16.95%+5.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.195.27% UpsideGILDGilead Sciences 2.86Moderate Buy$156.9320.25% UpsideMRNAModerna 1.84Reduce$35.73-24.39% DownsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$792.6523.35% UpsideCurrent Analyst Ratings BreakdownLatest AMGN, REGN, GILD, and MRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/20/2026GILDGilead Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$165.005/19/2026GILDGilead Sciences Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$161.00 ➝ $150.005/19/2026REGNRegeneron Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,057.00 ➝ $875.005/18/2026REGNRegeneron Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$900.00 ➝ $730.005/18/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$796.00 ➝ $778.005/18/2026REGNRegeneron Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$950.00 ➝ $850.005/18/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$762.00 ➝ $707.005/18/2026REGNRegeneron Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$800.00 ➝ $700.005/18/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$875.00 ➝ $855.005/18/2026REGNRegeneron Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$900.00 ➝ $700.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.95$34.50 per share9.78$17.03 per share19.81GILDGilead Sciences$29.44B5.50$10.47 per share12.46$18.87 per share6.92MRNAModerna$1.94B9.65N/AN/A$18.67 per share2.53REGNRegeneron Pharmaceuticals$14.34B4.74$42.78 per share15.02$297.23 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.4814.323.3220.96%137.41%13.28%8/4/2026 (Estimated)GILDGilead Sciences$8.51B$7.3417.7813.57N/A30.99%48.19%18.28%8/6/2026 (Estimated)MRNAModerna-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)REGNRegeneron Pharmaceuticals$4.50B$41.0415.6615.491.4029.65%13.16%10.17%7/30/2026 (Estimated)Latest AMGN, REGN, GILD, and MRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GILDGilead Sciences$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion5/1/2026Q1 2026MRNAModerna-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.082.99%+8.27%70.15%14 YearsGILDGilead Sciences$3.282.51%+3.04%44.69%10 YearsMRNAModernaN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.760.59%N/A9.16%N/ALatest AMGN, REGN, GILD, and MRNA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GILDGilead Sciencesquarterly$0.822.45%6/15/20266/15/20266/29/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/20264/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.58%5/20/20265/20/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01GILDGilead Sciences0.891.971.77MRNAModerna0.082.412.35REGNRegeneron Pharmaceuticals0.063.572.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%GILDGilead Sciences83.67%MRNAModerna75.33%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%GILDGilead Sciences0.30%MRNAModerna10.80%REGNRegeneron Pharmaceuticals6.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableGILDGilead Sciences17,0001.24 billion1.24 billionOptionableMRNAModerna4,700396.79 million353.93 millionOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableAMGN, REGN, GILD, and MRNA HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN40 minutes ago | prnewswire.comRegeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis1 hour ago | quiverquant.comQLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis2 hours ago | finance.yahoo.comLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis2 hours ago | globenewswire.comJim Cramer on Regeneron: “There Could Be Some More Downgrades”May 21 at 12:15 PM | finance.yahoo.comLevi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)May 21 at 9:00 AM | globenewswire.comATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospectsMay 20 at 3:40 PM | clinicaltrialsarena.comCRegeneron’s REGN7544 Trial Reaches Key Milestone in Sepsis-Induced HypotensionMay 20 at 12:30 PM | tipranks.comREGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities FraudMay 20 at 9:00 AM | businesswire.comTredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGNMay 20 at 6:56 AM | marketbeat.comResona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 20 at 5:25 AM | marketbeat.comProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 20 at 5:15 AM | marketbeat.comHarvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 20 at 3:55 AM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGNMay 20 at 3:54 AM | marketbeat.comWhy Regeneron Pharmaceuticals, Inc.’s (REGN) Stock Is Down 10.63%May 19 at 11:07 PM | aaii.comARegeneron sinks 10% on failed phase 3 melanoma trial. What comes next for REGN stock?May 19 at 11:07 PM | msn.comWhy Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its GoalMay 19 at 11:07 PM | finance.yahoo.comRegeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BMay 19 at 6:06 PM | finance.yahoo.comRegeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BMay 19 at 3:30 PM | zacks.comA Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price PullbackMay 19 at 1:05 PM | finance.yahoo.comCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?May 19 at 12:56 PM | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMGN, REGN, GILD, and MRNA Company DescriptionsAmgen NASDAQ:AMGN$337.42 +5.85 (+1.76%) Closing price 04:00 PM EasternExtended Trading$337.44 +0.02 (+0.01%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Gilead Sciences NASDAQ:GILD$130.50 -0.19 (-0.15%) Closing price 04:00 PM EasternExtended Trading$131.36 +0.87 (+0.66%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.Moderna NASDAQ:MRNA$47.26 -0.86 (-1.79%) Closing price 04:00 PM EasternExtended Trading$47.34 +0.09 (+0.18%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Regeneron Pharmaceuticals NASDAQ:REGN$642.59 -7.17 (-1.10%) Closing price 04:00 PM EasternExtended Trading$648.22 +5.63 (+0.88%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
